Valuation: Sutro Biopharma, Inc.

Market Cap 493M 431M 397M 367M 697M 46.99B 708M 4.75B 1.86B 23.15B 1.85B 1.81B 79.57B P/E 2026 *
-3.48x
P/E 2027 * -4.05x
Enterprise Value 493M 431M 397M 367M 697M 46.99B 708M 4.75B 1.86B 23.15B 1.85B 1.81B 79.57B EV / Sales 2026 *
11.1x
EV / Sales 2027 * 15.6x
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * -
1 day-0.87%
1 week-2.30%
Current month-10.45%
1 month+12.27%
3 months+14.97%
6 months+143.09%
Current year+156.96%
1 week 27.8
Extreme 27.8
33.35
1 month 27.1
Extreme 27.095
34.05
Current year 10.15
Extreme 10.15
43.85
1 year 7.15
Extreme 7.15
43.85
3 years 5.23
Extreme 5.231
61.3
5 years 5.23
Extreme 5.231
237
10 years 5.23
Extreme 5.231
283
Manager TitleAgeSince
Chief Executive Officer 55 2025-03-12
Director of Finance/CFO 53 2025-06-01
Chief Tech/Sci/R&D Officer - 2025-12-31
Director TitleAgeSince
Director/Board Member 70 2009-07-31
Director/Board Member 67 2017-01-31
Director/Board Member 51 2018-07-24
Date Insider Type Main position Quantity % Market Cap.
06-04Free

Director

10,000 0.0603%
06-04Free

Director

10,000 0.0603%
06-04Free

Director

10,000 0.0603%
Change 5-day change 1-year change 3-year change Capi.($)
-0.87%-2.30%+290.41%-36.88% 493M
+1.84%-0.66%+59.82%+92.96% 54.88B
-4.14%-8.06%+58.96%+118.67% 54.63B
-2.24%+3.59%+17.75%+477.47% 25.06B
-1.60%-6.21%-18.96%-15.21% 23.14B
+2.43%+1.06%+42.44%-1.27% 19.87B
-3.19%0.00%+35.60%-26.98% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
+8.74%+3.51%+51.91%+726.40% 15.75B
-1.05%+1.16%+25.95%+194.27% 14.2B
Average -0.69%-0.48%+75.90%+188.66% 24.21B
Weighted average by Cap. -0.89%-1.45%+51.75%+176.70%

Financials

2026 *2027 *
Net sales 44.56M 38.98M 35.95M 33.21M 63.01M 4.25B 64.07M 430M 169M 2.09B 167M 164M 7.2B 31.56M 27.6M 25.46M 23.52M 44.62M 3.01B 45.37M 304M 119M 1.48B 118M 116M 5.1B
Net income -137M -120M -111M -102M -194M -13.1B -197M -1.32B -520M -6.45B -516M -504M -22.18B -150M -132M -121M -112M -213M -14.35B -216M -1.45B -569M -7.07B -565M -552M -24.3B
Net Debt - -
Logo Sutro Biopharma, Inc.
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
Employees
133
Date Price Change Volume
26-07-10 US$29.73 -0.87% 242,434
26-07-09 US$29.99 -5.81% 248,243
26-07-08 US$31.84 -0.90% 424,160
26-07-07 US$32.13 +4.90% 583,318
26-07-06 US$30.63 +0.66% 382,469
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
29.73USD
Average target price
47.75USD
Spread / Average Target
+60.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STRO Stock